Cargando…

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

Chimeric antigen receptor T cells (CAR-T cell) targeting CD19 are effective against several subtypes of CD19-expressing hematologic malignancies. Centralized manufacturing has allowed rapid expansion of this cellular therapy, but it may be associated with treatment delays due to the required logisti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Zachary, Roe, Anne, Sharma, Ashish Arunkumar, Lopes, Filipa Blasco Tavares Pereira, Talla, Aarthi, Kleinsorge-Block, Sarah, Zamborsky, Kayla, Schiavone, Jennifer, Manjappa, Shivaprasad, Schauner, Robert, Lee, Grace, Liu, Ruifu, Caimi, Paolo F., Xiong, Ying, Krueger, Winfried, Worden, Andrew, Kadan, Mike, Schneider, Dina, Orentas, Rimas, Dropulic, Boro, Sekaly, Rafick-Pierre, de Lima, Marcos, Wald, David N., Reese, Jane S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427107/ https://www.ncbi.nlm.nih.gov/pubmed/32849651 http://dx.doi.org/10.3389/fimmu.2020.01941

Ejemplares similares

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
por: Caimi, Paolo F., et al.
Publicado: (2021)

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
por: Maschan, Michael, et al.
Publicado: (2021)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells
por: Paugh, Barbara S., et al.
Publicado: (2021)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
por: Schneider, Dina, et al.
Publicado: (2017)

In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells
por: Anthony-Gonda, Kim, et al.
Publicado: (2022)

Chimeric engulfment receptors: A new cell therapy approach for SIV and HIV infection
por: Orentas, Rimas J.
Publicado: (2023)

Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation
por: Pandiyan, Pushpa, et al.
Publicado: (2016)

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
por: Ojo, Evelyn O., et al.
Publicado: (2019)

Advances in Lentiviral Vector-based Cell Therapy with Mesenchymal Stem Cells
por: Baranyi, Lajos, et al.
Publicado: (2012)

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
por: Sekaly, Rafick-Pierre
Publicado: (2008)

Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4(+) T Cells
por: Kulpa, Deanna A., et al.
Publicado: (2019)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells
por: Zeng, Ke, et al.
Publicado: (2023)

Enhanced glycolytic metabolism is associated with exhaustion and poor antitumor efficacy in a xenograft model of chimeric antigen receptor T cell therapy for sarcoma
por: Long, Adrienne H, et al.
Publicado: (2013)

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2023)

Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection
por: LATIF, MUHAMMAD BILAL, et al.
Publicado: (2022)

Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination
por: Fourati, Slim, et al.
Publicado: (2016)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22
por: Sun, Zehua, et al.
Publicado: (2022)

Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
por: Gavegnano, Christina, et al.
Publicado: (2017)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
por: Fourati, Slim, et al.
Publicado: (2019)

Paracrine Transfer of Mouse Mammary Tumor Virus Superantigen
por: Delcourt, Marc, et al.
Publicado: (1997)

Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines
por: Pelletier, Adam N, et al.
Publicado: (2022)

Towards a commercial process for the manufacture of genetically modified T cells for therapy
por: Kaiser, A D, et al.
Publicado: (2015)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors
por: Highfill, Steven L, et al.
Publicado: (2013)

Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
por: Walker, Alec, et al.
Publicado: (2014)

Early Activation of Caspases during T Lymphocyte Stimulation Results in Selective Substrate Cleavage in Nonapoptotic Cells
por: Alam, Antoine, et al.
Publicado: (1999)

Highly Biased CDR3 Usage in Restricted Sets of β Chain Variable Regions During Viral Superantigen 9 Response
por: Ciurli, Cristina, et al.
Publicado: (1998)

A systems framework for vaccine design
por: Mooney, Michael, et al.
Publicado: (2013)

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
por: Tian, Meijie, et al.
Publicado: (2023)

Myeloid Cells Enriched for a Dendritic Cell Population From People Living With HIV Have Altered Gene Expression Not Restored by Antiretroviral Therapy
por: Murray, Shannon M., et al.
Publicado: (2020)

Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
por: Orentas, Rimas J., et al.
Publicado: (2012)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_69pkfh1ai2tkid446cgo64onra